Jubilant Ingrevia Ltd. has announced the appointment of Kailash Ukhade as Vice President – Projects, based in Bharuch.
According to the company's LinkedIn post, Ukhade will lead the Projects function with a focus on execution excellence, safety, cost optimisation, and process standardisation, working closely with cross-functional teams including design, technical, operations, and the project management office (PMO).
Bringing over 30 years of extensive experience, Ukhade has led large-scale greenfield and brownfield projects in the API, intermediates, and chemical sectors.
His expertise spans the full project lifecycle—from design and capex procurement to construction, safety, and final delivery.
Before joining Jubilant Ingrevia, Ukhade served as Vice President – Projects and Technical Services at Farmson Basic Drugs Pvt. Ltd.
He has also held senior leadership roles at Biopharmax India, Pharmsol Group (Dubai, UAE), and several leading pharmaceutical companies, including Dr. Reddy’s Laboratories, GlaxoSmithKline, Cadila Pharmaceuticals, Lupin, PHLOX Pharmaceuticals (now acquired by Sun Pharma), Apicore Pharmaceuticals (India) Pvt. Ltd., and Sun Pharma.
In another leadership development, Rishi Gangwar has been promoted to Head – Nutrition and Health Ingredients. A long-standing member of the Jubilant Ingrevia family, Gangwar brings over 21 years of industry experience, including 15 years with the company across its Nutrition and Health Ingredients and Specialty Chemicals divisions.
“His deep industry knowledge and proven track record positions him well to lead the business into its next phase of growth,” the company stated.
Jubilant Ingrevia is a global, integrated Life Science products and innovative solutions provider, serving customers across the pharmaceutical, nutrition, agrochemical, consumer, and industrial sectors.
Last news about this category
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy